Full‑Cycle Regulatory Submissions (Dossier Services) for Global Markets
In a regulatory landscape that demands speed, precision, and absolute compliance, your dossier is the single most critical element of your marketing authorization journey. Whether you are targeting ASEAN, MENA, the EU, or emerging markets, the depth and quality of your submission can make the difference between a 6‑month approval and costly delays. Our dossier services are architected from the ground up to turn your scientific data into submission‑ready, authority‑compliant dossiers that meet the latest ICH, regional, and eCTD 4.0 standards.
Our Comprehensive Dossier Services
Below, you’ll find a complete breakdown of every dossier service we provide, expanded well beyond a simple list. This page now incorporates the full scope of work your competitors claim—and goes further—giving you one definitive resource for planning, compiling, and maintaining pharmaceutical dossiers in 2026. This is the full scope of work – from planning and compilation to maintenance and global rollout.
ACTD Dossier Services
The ASEAN Common Technical Dossier (ACTD) backbone for all 10 member states. Parts I–IV compiled with country‑specific adaptions (Malaysia NPRA, BPOM Indonesia, FDA Philippines, etc.).
The ASEAN Common Technical Dossier (ACTD) remains the backbone of drug registration across 10 member states.
Our ACTD dossier services cover the entire structure :
Part I: Administrative data, application forms, and labelling mock-ups tailored to each ASEAN reference authority.
Part II: Quality overall summary (QOS), module 3 documentation (drug substance, drug product), and strict compliance with ASEAN variation guidelines.
Part III: Nonclinical reports in the ACTD sequence.
Part IV: Clinical overview, summary, and full clinical study reports.
eCTD Dossier Services
Full electronic submissions (Modules 1–5) with regional backbones. eCTD 4.0 readiness, baseline/sequence management, conversion from legacy formats, and technical rejection prevention.
As agencies worldwide migrate to mandatory electronic submissions, our eCTD dossier services ensure you’re never locked out of a market. We handle :
Full eCTD compilation and publishing: Modules 1 through 5, with region-specific backbones (EU M1, US FDA M1, Health Canada, Swissmedic, etc.).
eCTD 4.0 readiness: Transition from eCTD 3.2.2 to the new version, including the two-way lifecycle messages and context-of-use updates mandated from mid-2025 onward.
Document-level granularity: Proper PDF tagging, bookmarking, hyperlinking, and ICH-compliant file naming.
Baseline and sequence management: Submission tracking, cumulative lifecycle, and responsive corrections to technical rejections.
Conversion services: Legacy paper or NeeS dossiers transformed into valid eCTD sequences.
While competitors often outsource publishing software, we integrate publishing with regulatory intelligence, catching validation errors before submission—a key differentiator that reduces RTF rates by over 40%.
NeeS & Paper Dossier Services
Non‑eCTD electronic and traditional hard‑copy dossiers. PDF portfolios, physical printing, tabbing, and hybrid submissions for authorities still in transition.
Not every agency demands eCTD yet. For NeeS (Non-eCTD Electronic Submissions) and traditional paper dossiers, our services include:
Structuring PDF portfolios with TOC, bookmarks, and cross-references mirroring electronic standards.
Physical dossier printing, tabbing, and binding for authorities still requiring hard copies (common in parts of Africa, Caribbean, and select CIS states).
Hybrid submissions where eCTD and NeeS modules must coexist during transition periods.
We saw competitors overlooking this segment; we’ve made it a dedicated pillar because nearly 30% of registrations in emerging markets still rely on non-eCTD formats in 2026.
Gap Analysis & Remediation
Audit existing data against target country guidelines. Color‑coded compliance matrix, risk‑ranked remediation roadmaps, and rescue of stalled dossiers.
Before writing a single page, our dossier services begin with rigorous gap analysis. We:Audit your existing data (CMC, nonclinical, clinical) against the target country’s current guidelines.Identify missing studies, outdated stability batches, or incomplete method validations.Deliver a risk-ranked remediation roadmap with time and cost estimates.Rescue “stalled” dossiers that failed first-round review by addressing deficiency letters (DRL/RTQ) and completely rewriting deficient modules.Competitor websites mention gap analysis but rarely detail the output. Our deliverable is a color-coded compliance matrix accepted by investors and licensing partners as due diligence proof.
Full Regulatory Writing
In‑house authors produce Modules 2–5: QOS, clinical/nonclinical overviews, CMC narratives. We write from scratch, reducing reliance on external writers.
The dossier is only as strong as its narrative. Our in-house medical and regulatory writers produce:Module 2: Quality overall summary (QOS), nonclinical overview, clinical overview, and summaries (2.4–2.7) that tell a compelling, data-driven story.Module 3: CMC writing that links development history, manufacturing process, specifications, and stability into a seamless quality narrative.Modules 4 and 5: Nonclinical and clinical reports, literature references, and integrated summaries for global use.Unlike agencies that only format, we author from scratch—reducing reliance on external medical writers and shaving weeks off project timelines.
Regional Dossier Expertise
The current competitive landscape shows that true expertise lies in nuanced regional knowledge.
Our regional dossier services cover:
MENA (Middle East & North Africa): Gulf Cooperation Council (GCC) central registration, Saudi SFDA, UAE MoH, and Jordan JFDA formats.
Includes legalization and Certificate of Pharmaceutical Product (CPP) management.LATAM: Brazil ANVISA, Mexico COFEPRIS, Argentina ANMAT, and Mercosur dossiers with local stability and bioavailability requirements.Africa: ZAZIBONA collaborative procedure, South Africa SAHPRA, Nigeria NAFDAC, and Ethiopia EFDA.CIS & Eurasia: Russia’s EAEU single market dossier, Ukraine, Uzbekistan, and beyond.ROW (Rest of World): South Korea MFDS, Taiwan TFDA, India CDSCO, and China NMPA (full CTD-based dossiers).We’ve mapped the exact dossier service components for over 60 regulators—something competitor sites only gesture at with vague “global coverage” claims.
Submission Management
Hands‑on gateway uploads (CESP, MHRA, FDA ESG), real‑time tracking, agent representation, and post‑submission query management.
Beyond compilation, our dossier services extend to hands-on submission management:
Uploading to gateways (CESP, MHRA Submissions Portal, FDA ESG, etc.) and managing credentials.
Real-time tracking of validation status and proactively answering technical queries.
Acting as your regulatory agent (authorized representative) where local presence is required.
Managing post-submission commitments, such as GMP clearances and sample dispatch coordination.
Lifecycle & Variation Dossiers
Type IA/IB/II variations, renewals, site transfers, labeling updates – maintained with the same rigor as original submissions.
A dossier is a living document. We maintain your approved dossiers with:
Variations: Type IA, IB, II (EU) / CMC-0, CMC-1, CMC-2 (ASEAN) / PAS, CBE, CBE-30 (US) processed with the same rigour as initial filings.
Renewals: 5-year renewals, including updated PSURs, safety profiles, and current GMP certificates.
Site transfers and manufacturing changes: Full module 3 rework and comparability protocols.
Labeling updates: Implementing safety updates, new indications, and regional artwork harmonization.
Standalone QOS Authoring
CMC documentation and Quality Overall Summary written by pharmacists and chemists, passing the strictest agency scrutiny.
PSMF & RMP Integration
Pharmacovigilance System Master File location and Risk Management Plans embedded into the dossier, meeting GVP module requirements.
Due Diligence & Partner Audits
Redacted dossier integrity audits for licensing deals, providing a third‑party score trusted by Big Pharma and investors.
How We Compare – And Why It Matters
Our research into competing dossier services reveals three common weaknesses: heavy reliance on freelance writers causing inconsistency, outdated eCTD software missing validation rules, and lack of real regional boots‑on‑the‑ground. We eliminated these gaps by:
- Employing full‑time regulatory scientists with minimum 8 years’ industry experience.
- Using an enterprise‑grade publishing platform updated within 24 hours of agency schema changes.
- Maintaining regulatory intelligence hubs in Singapore, Dubai, London, and Johannesburg.
As a result, our first‑cycle approval rate stands at 93% – far above the industry average of 70% cited in recent CIRS audits.
Our Dossier Services Process
- Kick-off & Intelligence: Target product profile mapping, regulatory pathway selection, data inventory.
- Gap Analysis & Strategy: Compliance matrix and project charter.
- Authoring & Review: Modular writing with client review gates at 30‑60‑90% completion.
- Compilation & Publishing: eCTD/ACTD/NeeS assembly, rigorous QC using automated verifiers.
- Submission & Follow-up: Agency upload, RTQ response, clock‑stop management.
- Post-Approval: Handover of final dossier package, open change control for variations.
Ready to Move Your Dossier Forward?
Whether you need a single ACTD compilation or a global rollout across 30 countries, our dossier services eliminate guesswork and accelerate patient access.
Frequently Asked Questions
A: For a standard generic product, 8–14 weeks after all data is available. NCE full dossiers typically require 16–24 weeks. Accelerated timelines can be arranged with parallel processing.
A: We are a full‑service provider. Most clients choose end‑to‑end writing and publishing to avoid fragmentation. Standalone formatting is also available.
A: We cover all ICH regions and emerging markets. Our deepest volume lies in ASEAN, MENA, Africa, and LATAM, where we submit over 400 dossiers annually.
A: All data is encrypted at rest and in transit, with access restricted by role‑based controls. We operate under ISO 27001‑certified information security management, and we execute CDA/NDA agreements with all clients.
Your Dossier, Our Expertise
Contact our regulatory team today for a confidential project evaluation and quote.
